Reply: Lorazepam-Induced Prolongation of the QT Interval in a Patient With Schizoaffective Disorder and Complete AV Block
Dear Editor: Thank you for the opportunity to respond to Dr Crockford's letter. As active members of a drug safety program in psychiatry in Europe (Arzneimittelsicherheit in der Psychiatrie [AMSP]), we are always interested in discussing complex cases of pharmacotherapy. The AMSP is a drug safety program that ensures the continual assessment of severe adverse drug reactions in psychiatric inpatients under the naturalistic conditions of routine clinical treatment (1) . The AMSP aims to collect information on the type and frequency of severe adverse drug reactions, to identify specific risk factors with regard to patient characteristics and such treatmentrelated factors as interactions caused by drug combinations or drug dosage, and to provide more information on how to adequately handle adverse drug reactions. Currently, 45 hospitals participate in the program.
Recent studies show that a high number of patients with severe cardiac drug reactions have frequent cardiac comorbidity (2) . In addition, most receive drug combinations wherein drugs with similar adverse reaction profiles are often coprescribed. We agree with Dr Crockford that the case we presented and discussed is definitely complex with preexisting cardiovascular risks. However, we do not agree that lorazepam is not possibly associated with QT prolongation in that particular case, and we would like to comment on a few of Dr Crockford's points. First, the electrolyte status revealed no abnormal findings, and the liver enzymes were moderately elevated. Second, the relevance of the half-life of lorazepam in relation to the duration of the QT prolongation is uncertain. Various undesired adverse drug reactions, for example skin reactions and blood dyscrasia, appear after single drug doses. Third, while we agree that a unique mechanism of action for lorazepam, distinct from the other benzodiazepines, seems to be unlikely, daily clinical work shows that substances with almost an identical chemical structure cause different side effects. Fourth, as Dr Crockford points out, there are multiple confounding factors; however, this does not preclude the possibility that lorazepam set off the mechanisms of the persisting QT prolongation.
Inspired by our work in the AMSP, we decided to present our provocative conclusions in this complex case. This case shows that, in patients taking drug combinations and having preexisting cardiovascular risks, physicians should be aware of possible unlikely adverse drug reactions. On our way from case reports to quality management of drug treatment, controversial discussions are important to classify severe adverse drug reactions. As well, further research is needed to elucidate the underlying physiological mechanisms. We definitely agree with Dr Crockford that clinicians should not change their practice with regard to lorazepam in general. Lorazepam is an important and useful drug in daily psychiatric clinical work. As with any drug, it can have side effects, some of which may be rare and peculiar.
Marc Ziegenbein, MD Stefan Kropp, MD Hanover, Germany

Lithium-Associated Anencephaly
Dear Editor: The most common congenital malformation (CMF) associated with lithium is Ebstein's anomaly. Other reported effects on the fetus are poor respiratory effort, cyanosis, rhythm disturbances, nephrogenic diabetes insipidus, thyroid dysfunction, hypoglycemia, hyperbilirubinemia, floppy baby syndrome, and large-for-gestational-age infants (1) . Neural tube defects have not been reported in humans.
Case Report
A woman, aged 21 years, with no medical or psychiatric history developed acute-onset manic illness that was initially treated with haloperidol (dosage unknown) and lasted for 3 weeks. She presented to our services with neuroleptic malignant syndrome and was treated with bromocriptine up to 15 mg daily, lorazepam up to 6 mg daily, and supportive management. She improved without any neurologic sequel and was started on lithium.
She remained euthymic on lithium 900 mg daily for 2 years (her serum levels were monitored regularly). She married during this period and had genetic counselling (wherein she was advised to practise contraception and to stop taking lithium if she planned a pregnancy). However, owing to contraceptive failure, she conceived. The patient and her husband decided to continue the pregnancy, despite repeat counselling. She stopped taking lithium before 8 completed weeks of pregnancy.
An investigation profile (specifically, HIV, Venereal Disease Research Laboratory slide test, TORCH Screen, hepatitis B antigen, hemogram, renal and liver function tests, and blood sugar level) was normal. She started taking folic acid, calcium, and iron supplements at approximately 8 weeks. Ultrasonography at 12 weeks showed a live fetus, aged 9 weeks. Ultrasonography at 20 weeks showed a live fetus, aged 16 weeks, with evidence of a supraorbital cranial bony defect (suggesting anencephaly) along with a Can J Psychiatry, Vol 50, No 3, March 2005 W 185
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